Aarti Drugs Limited
NSE: AARTIDRUGS BSE: AARTIDRUGS
NSE
361.65
4.20 (1.17%)
Prev Close
357.45
Open Price
358.1
Volume
101,872
Today Low / High
355.6 / 363.85
52 WK Low / High
312 / 635
Range
344 - 380
BSE
362.15
4.70 (1.31%)
Prev Close
357.45
Open Price
363.95
Volume
15,746
Today Low / High
355.65 / 363.95
52 WK Low / High
312.5 / 632.1
Range
344 - 380
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 361.65 (target range: 344 - 380), reflecting a change of 4.2 (1.17499%). On the BSE, it is listed at 362.15 (target range: 344 - 380), showing a change of 4.7 (1.31487%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
21 Apr
358.10
0.99%
17 Apr
359.50
-0.57%
16 Apr
350.50
2.21%
15 Apr
333.00
6.68%
11 Apr
330.60
-0.44%
09 Apr
330.30
-2.39%
08 Apr
327.50
0.85%
07 Apr
317.00
1.50%
04 Apr
348.50
-4.48%
03 Apr
342.00
1.90%
02 Apr
346.55
-1.17%
01 Apr
340.00
0.91%
28 Mar
353.00
-3.60%
27 Mar
335.00
5.40%
26 Mar
345.80
-3.51%
25 Mar
358.00
-3.78%
24 Mar
363.00
-1.86%
Aarti Drugs Limited Graph
Aarti Drugs Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Aarti Drugs Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 361.65, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 362.15 | 365.77 | 329.19 - 402.35 |
| 369.39 | 295.51 - 443.27 | ||
| 373.01 | 261.11 - 484.92 | ||
| Bearish Scenario | 362.15 | 358.53 | 322.68 - 394.38 |
| 354.91 | 283.93 - 425.89 | ||
| 351.29 | 245.90 - 456.67 |
Overview of Aarti Drugs Limited
ISIN
INE767A01016
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
166,502
Market Cap
33,007,795,500
Last Dividend
1
Official Website
IPO Date
2003-09-19
DCF Diff
103.19
DCF
258
Financial Ratios Every Investor Needs
Stock Dividend of AARTIDRUGS
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-02-04 | February 04, 25 | 1 | 1 | 2025-02-04 | 2025-02-28 | |
| 2024-02-06 | February 06, 24 | 1 | 1 | 2024-02-06 | 2024-02-23 | |
| 2023-02-08 | February 08, 23 | 1 | 1 | 2023-02-08 | 2023-02-26 | |
| 2022-02-09 | February 09, 22 | 1 | 1 | 2022-02-10 | 2022-03-02 | |
| 2020-11-03 | November 03, 20 | 2.5 | 2.5 | 2020-11-04 | 2020-11-22 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 2,508.87 Cr | 2,157.71 Cr | 351.17 Cr | 0.1400 | 0.00 Cr | 14.18 Cr | 277.70 Cr | 171.42 Cr | 18.56 | 320.49 Cr | 0.0683 |
| 2023-03-31 | 2,716.05 Cr | 1,888.51 Cr | 827.54 Cr | 0.3047 | 7.75 Cr | 13.37 Cr | 256.77 Cr | 166.31 Cr | 17.96 | 311.64 Cr | 0.0612 |
| 2022-03-31 | 2,488.65 Cr | 1,984.82 Cr | 503.83 Cr | 0.2024 | 6.61 Cr | 13.23 Cr | 288.39 Cr | 205.04 Cr | 22.14 | 343.91 Cr | 0.0824 |
| 2021-03-31 | 2,154.78 Cr | 1,554.47 Cr | 600.31 Cr | 0.2786 | 8.60 Cr | 9.44 Cr | 388.13 Cr | 280.41 Cr | 30.09 | 445.13 Cr | 0.1301 |
| 2020-03-31 | 1,806.09 Cr | 1,401.83 Cr | 404.26 Cr | 0.2238 | 8.74 Cr | 8.08 Cr | 213.42 Cr | 141.40 Cr | 15.17 | 271.47 Cr | 0.0783 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 6.74 Cr | 2,432.36 Cr | 1,150.40 Cr | 1,281.5485 Cr | 564.28 Cr | 557.54 Cr | 485.89 Cr | 1,053.94 Cr | 0.00 Cr | 0.00 Cr | 19.97 Cr | 795.5427 Cr |
| 2023-03-31 | 8.96 Cr | 2,421.40 Cr | 1,228.74 Cr | 1,192.4300 Cr | 608.91 Cr | 599.95 Cr | 516.29 Cr | 885.79 Cr | 4.37 Cr | 0.17 Cr | 18.80 Cr | 932.9800 Cr |
| 2022-03-31 | 21.61 Cr | 2,207.96 Cr | 1,171.66 Cr | 1,036.3611 Cr | 542.82 Cr | 521.20 Cr | 525.94 Cr | 766.52 Cr | 112.45 Cr | 0.17 Cr | 19.48 Cr | 940.0581 Cr |
| 2021-03-31 | 8.81 Cr | 1,766.01 Cr | 852.61 Cr | 913.4246 Cr | 350.76 Cr | 341.95 Cr | 415.00 Cr | 684.40 Cr | -39.61 Cr | 0.17 Cr | 17.30 Cr | 595.3559 Cr |
| 2020-03-31 | 6.77 Cr | 1,576.50 Cr | 924.01 Cr | 652.4894 Cr | 388.64 Cr | 381.87 Cr | 325.40 Cr | 654.53 Cr | 92.70 Cr | 0.17 Cr | 13.36 Cr | 624.7006 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 358.9232 Cr | -223.6508 Cr | -136.0331 Cr | 132.5887 Cr | -0.7607 Cr | 6.7427 Cr | -226.3345 Cr | 171.4182 Cr | -22.2845 Cr | -9.2673 Cr | 34.2458 Cr |
| 2023-03-31 | 134.2000 Cr | -163.9700 Cr | 16.5400 Cr | -30.4700 Cr | -13.2300 Cr | 8.3800 Cr | -164.6700 Cr | 224.1800 Cr | 61.3741 Cr | -9.4013 Cr | 5.8200 Cr |
| 2022-03-31 | 69.6357 Cr | -148.8616 Cr | 92.0251 Cr | -82.3392 Cr | 12.7991 Cr | 21.6120 Cr | -151.9749 Cr | 269.9551 Cr | 195.9490 Cr | -9.5077 Cr | -110.6302 Cr |
| 2021-03-31 | 154.8497 Cr | -71.6790 Cr | -81.1290 Cr | 66.7189 Cr | 2.0417 Cr | 8.8130 Cr | -88.1308 Cr | 369.0139 Cr | -34.9667 Cr | -23.2052 Cr | -89.1849 Cr |
| 2020-03-31 | 250.7438 Cr | -33.2093 Cr | -215.4067 Cr | 202.7532 Cr | 2.1278 Cr | 6.7713 Cr | -47.9906 Cr | 185.2885 Cr | -147.8249 Cr | -8.4668 Cr | -78.6888 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 556.60 Cr | 351.39 Cr | 205.21 Cr | 0.3687 | 47.93 Cr | 37.05 Cr | 4.06 | 73.63 Cr | 0.0666 |
| 2024-09-30 | 598.33 Cr | 434.28 Cr | 164.05 Cr | 0.2742 | 53.32 Cr | 35.01 Cr | 3.83 | 68.53 Cr | 0.0585 |
| 2024-06-30 | 555.34 Cr | 399.63 Cr | 155.71 Cr | 0.2804 | 51.57 Cr | 33.24 Cr | 3.62 | 66.06 Cr | 0.0599 |
| 2024-03-31 | 619.99 Cr | 436.55 Cr | 183.44 Cr | 0.2959 | 72.23 Cr | 47.31 Cr | 5.15 | 86.89 Cr | 0.0763 |
| 2023-12-31 | 605.94 Cr | 405.24 Cr | 200.70 Cr | 0.3312 | 59.15 Cr | 36.67 Cr | 3.99 | 71.80 Cr | 0.0605 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 11.34 Cr | 18.22 Cr | 29.56 Cr | 682.81 Cr | 470.00 Cr | 1,255.88 Cr | 1,134.06 Cr | 2,429.55 Cr | 1,151.76 Cr |
| 2024-06-30 | -20.77 Cr | 41.54 Cr | 20.77 Cr | 0.00 Cr | 0.00 Cr | 20.77 Cr | 0.00 Cr | 0.00 Cr | -1,281.97 Cr |
| 2024-03-31 | 9.43 Cr | 14.03 Cr | 9.43 Cr | 709.51 Cr | 485.89 Cr | 1,320.72 Cr | 1,035.14 Cr | 2,432.36 Cr | 1,150.40 Cr |
| 2023-12-31 | -24.99 Cr | 49.98 Cr | 24.99 Cr | 0.00 Cr | 0.00 Cr | 24.99 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 12.72 Cr | 12.27 Cr | 24.99 Cr | 703.57 Cr | 515.23 Cr | 1,338.10 Cr | 972.91 Cr | 2,351.83 Cr | 1,142.03 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | 33.24 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 47.37 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 36.67 Cr | 25.32 Cr | 0.00 Cr | 0.00 Cr | 25.32 Cr | 38.04 Cr | 12.72 Cr | 0.00 Cr | 25.32 Cr |
| 2023-09-30 | 39.59 Cr | 25.22 Cr | 0.00 Cr | 0.00 Cr | 25.22 Cr | 12.72 Cr | -12.50 Cr | 0.00 Cr | 25.22 Cr |
| 2023-06-30 | 47.85 Cr | 25.20 Cr | 0.00 Cr | 0.00 Cr | 25.20 Cr | 34.16 Cr | 8.96 Cr | 0.00 Cr | 25.20 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2020-09-30 | September 30, 20 | 4:1 |
| 2015-03-24 | March 24, 15 | 2:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,744.90 | ₹4,186,497,390,360.00 | ₹1,539,404.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹5,891.50 | ₹1,564,008,080,155.00 | ₹717,304.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,254.60 | ₹1,101,504,496,478.00 | ₹168,941.00 |
| Mankind Pharma Limited | MANKIND | ₹2,588.40 | ₹1,067,918,241,168.00 | ₹342,053.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,177.40 | ₹980,907,622,968.00 | ₹1,938,682.00 |
| Lupin Limited | LUPIN | ₹2,009.20 | ₹917,330,458,276.00 | ₹966,589.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹845.35 | ₹850,616,530,500.00 | ₹1,860,605.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,201.20 | ₹697,658,929,968.00 | ₹653,310.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,000.40 | ₹597,872,826,000.00 | ₹97,948.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,368.80 | ₹386,259,126,032.00 | ₹2,163,260.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,423.80 | ₹361,224,068,436.00 | ₹163,712.00 |
| Laurus Labs Limited | LAURUSLABS | ₹640.35 | ₹345,310,338,375.00 | ₹1,671,228.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,679.20 | ₹334,664,498,320.00 | ₹44,703.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,202.20 | ₹306,037,994,912.00 | ₹330,131.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,658.70 | ₹258,221,804,814.00 | ₹100,079.00 |
| Piramal Enterprises Limited | PEL | ₹1,039.85 | ₹234,462,986,345.00 | ₹552,041.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,401.40 | ₹227,698,028,558.00 | ₹264,593.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,727.50 | ₹218,187,500,000.00 | ₹13,476.00 |
| Eris Lifesciences Limited | ERIS | ₹1,382.90 | ₹188,299,218,053.00 | ₹81,150.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,136.00 | ₹168,533,566,400.00 | ₹53,273.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹849.65 | ₹167,009,863,405.00 | ₹223,768.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹829.80 | ₹148,625,361,828.00 | ₹383,129.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹915.95 | ₹145,893,560,183.00 | ₹228,298.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,906.70 | ₹144,931,500,763.00 | ₹146,966.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹480.20 | ₹116,469,494,344.00 | ₹1,207,487.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,223.50 | ₹86,706,866,654.00 | ₹3,571.00 |
| FDC Limited | FDC | ₹430.60 | ₹70,106,024,754.00 | ₹67,489.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹712.85 | ₹64,608,888,867.00 | ₹374,808.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹658.10 | ₹64,356,197,871.00 | ₹163,074.00 |
| Strides Pharma Science Limited | STAR | ₹640.75 | ₹59,053,256,433.00 | ₹243,236.00 |
| Innova Captab Limited | INNOVACAP | ₹915.85 | ₹52,409,452,141.00 | ₹37,786.00 |
| Hikal Limited | HIKAL | ₹423.80 | ₹52,254,857,850.00 | ₹371,223.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹152.84 | ₹49,599,942,480.00 | ₹505,473.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹633.90 | ₹44,630,236,620.00 | ₹75,809.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹799.75 | ₹40,562,604,224.00 | ₹101,985.00 |
| Sequent Scientific Limited | SEQUENT | ₹148.17 | ₹37,087,247,340.00 | ₹527,793.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,179.20 | ₹36,041,821,488.00 | ₹10,217.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹349.90 | ₹35,087,098,650.00 | ₹40,163.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹361.65 | ₹33,007,795,500.00 | ₹101,872.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹53.91 | ₹29,540,183,967.00 | ₹4,747,370.00 |
| Suven Life Sciences Limited | SUVEN | ₹127.13 | ₹27,723,712,024.00 | ₹173,057.00 |
| Alembic Limited | ALEMBICLTD | ₹105.35 | ₹27,051,965,791.00 | ₹436,085.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹520.70 | ₹25,021,207,514.00 | ₹37,558.00 |
Key Executives
Managing Director of the Pinnacle Life Science Private Limited
Mr. Vishwa Harshit Savla
Gender: male
Year Born:
Whole-Time Director
Mr. Harit Pragji Shah
Gender: male
Year Born: 1963
Chairman, MD, Chief Executive Officer & Head of BR
Mr. Prakash Moreshwar Patil
Gender: male
Year Born: 1947
Chief Financial Officer & Chief Operating Officer
Mr. Adhish Prakash Patil
Gender: male
Year Born: 1983
Company Secretary & Compliance Officer
Mr. Rushikesh Vivek Deole
Gender: male
Year Born:
Vice President of Technical
Mr. Dhanaji L. Kakade
Gender: male
Year Born:
Joint MD & Executive Director
Mr. Harshit Manila Savla
Gender: male
Year Born: 1962
Whole-Time Director
Mr. Uday Moreshwar Patil
Gender: male
Year Born: 1963
MD & Executive Director
Mr. Rashesh Chandrakant Gogri
Gender: male
Year Born: 1974
FAQs about Aarti Drugs Limited
Who is the CEO of the company?
The CEO is Mr. Prakash Moreshwar Patil.
What is the current market price of the stock?
The current price is ₹361.65.
What is the 52-week price range?
The range is ₹312-635.
What is the market capitalization of the company?
The market capitalization is ₹3,300.78 crores.
What is the dividend yield?
The dividend yield is 0.28%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 21.63.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Aarti Drugs Limited (ISIN: INE767A01016) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹3,300.78 crores and an average daily volume of 166,502 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹1.